AI Engines For more Details: Perplexity Kagi Labs You
Breast Cancer: Toremifene is classified as a selective estrogen receptor modulator (SERM). It works by blocking the effects of estrogen in breast tissue, thereby inhibiting the growth of estrogen-dependent breast cancer cells. Toremifene is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive tumors. It may also be used as adjuvant therapy to reduce the risk of breast cancer recurrence following surgery or other primary treatments.
Estrogen Receptor-Positive Breast Cancer: Toremifene is particularly effective in treating estrogen receptor-positive breast cancer, where estrogen promotes the growth of cancer cells. By blocking estrogen receptors in breast tissue, toremifene helps slow down or stop the progression of hormone-sensitive breast cancer.
Metastatic Breast Cancer: Toremifene is used in the treatment of metastatic breast cancer, where cancer cells have spread to other parts of the body beyond the breast. It may help slow down the progression of the disease and alleviate symptoms associated with advanced breast cancer.
Adjuvant Therapy: Toremifene may be prescribed as adjuvant therapy in combination with other treatments such as surgery, chemotherapy, or radiation therapy. Adjuvant therapy aims to reduce the risk of cancer recurrence and improve long-term outcomes in patients who have undergone primary treatment for breast cancer.
Bone Health: Toremifene has been shown to have beneficial effects on bone health in postmenopausal women with breast cancer. It may help prevent bone loss and reduce the risk of osteoporosis, a common complication of breast cancer treatment and menopause.
Endometrial Cancer: Like other SERMs, toremifene may increase the risk of endometrial cancer or uterine abnormalities in some women. Regular gynecological monitoring is recommended during treatment with toremifene to detect any potential changes in the uterus and endometrium.
Thromboembolic Events: Toremifene, similar to other SERMs, may increase the risk of thromboembolic events such as blood clots in veins (deep vein thrombosis) or arteries (pulmonary embolism). Patients should be monitored for signs and symptoms of thromboembolism during treatment.
Hot Flashes: Toremifene may cause or exacerbate menopausal symptoms such as hot flashes, night sweats, and vaginal dryness. These side effects are often transient and may improve over time or with supportive measures.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 4.2 | 0.6 | 6 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.6 | 1.7 | 0.53 |
| Allergies | 5.7 | 3.2 | 0.78 |
| Allergy to milk products | 1.2 | 1 | 0.2 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.2 | 6.3 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.3 | 7 |
| Ankylosing spondylitis | 3.4 | 1.8 | 0.89 |
| Anorexia Nervosa | 1.4 | 2.7 | -0.93 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 4.5 | 1.9 | 1.37 |
| Atherosclerosis | 2.1 | 1.7 | 0.24 |
| Atrial fibrillation | 3.8 | 2.5 | 0.52 |
| Autism | 8.6 | 8.7 | -0.01 |
| Autoimmune Disease | 0.6 | 0.8 | -0.33 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.9 | 0.9 | |
| Bipolar Disorder | 1.3 | 1.1 | 0.18 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.6 | 0.3 | 1 |
| Cancer (General) | 0.3 | 2.1 | -6 |
| Carcinoma | 3.2 | 2.3 | 0.39 |
| Celiac Disease | 2.4 | 3.2 | -0.33 |
| Cerebral Palsy | 0.9 | 1.3 | -0.44 |
| Chronic Fatigue Syndrome | 4 | 6.8 | -0.7 |
| Chronic Kidney Disease | 3.4 | 2.9 | 0.17 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 1.7 | -0.13 |
| Chronic Urticaria (Hives) | 0.3 | 1.2 | -3 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.6 | 1.1 | 2.27 |
| Colorectal Cancer | 6.2 | 2 | 2.1 |
| Constipation | 1.5 | 1.3 | 0.15 |
| Coronary artery disease | 1.8 | 2.5 | -0.39 |
| COVID-19 | 7.4 | 11.1 | -0.5 |
| Crohn's Disease | 7 | 5.5 | 0.27 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.8 | -1.8 | |
| deep vein thrombosis | 1.9 | 1.4 | 0.36 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 9 | 8.8 | 0.02 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.2 | 2.3 | -0.92 |
| Endometriosis | 2.3 | 1.4 | 0.64 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.2 | 1.7 | 0.29 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 2.6 | 2.4 | 0.08 |
| Functional constipation / chronic idiopathic constipation | 4.6 | 4.1 | 0.12 |
| gallstone disease (gsd) | 2.6 | 1.1 | 1.36 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.2 | 0.25 |
| Generalized anxiety disorder | 1.9 | 2.3 | -0.21 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.6 | 0.5 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.7 | 1.5 | -1.14 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.6 | 1.8 | 1 |
| Heart Failure | 3.5 | 1.9 | 0.84 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 0.5 | 0.6 | -0.2 |
| hyperglycemia | 0.6 | 1.1 | -0.83 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.1 | 6 | -0.46 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 1.6 | 0.9 | 0.78 |
| IgA nephropathy (IgAN) | 1.6 | 3.9 | -1.44 |
| Inflammatory Bowel Disease | 6.2 | 9.5 | -0.53 |
| Insomnia | 2.2 | 2.1 | 0.05 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 5.5 | 4.2 | 0.31 |
| ischemic stroke | 2.3 | 1.1 | 1.09 |
| Liver Cirrhosis | 5.8 | 3.2 | 0.81 |
| Long COVID | 5.6 | 8.4 | -0.5 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | 1 | -2.33 |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 0.9 | 2.4 | -1.67 |
| ME/CFS without IBS | 0.9 | 2.4 | -1.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.5 | 0.5 | 2 |
| Metabolic Syndrome | 6.4 | 7.6 | -0.19 |
| Mood Disorders | 7.8 | 7 | 0.11 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 5 | 6.2 | -0.24 |
| Multiple system atrophy (MSA) | 0.6 | 0.7 | -0.17 |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 2.5 | -2.5 | |
| Neuropathy (all types) | 0.4 | 1.6 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 4.5 | -0.25 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 8.9 | 7.5 | 0.19 |
| obsessive-compulsive disorder | 5 | 4 | 0.25 |
| Osteoarthritis | 1.9 | 1.2 | 0.58 |
| Osteoporosis | 1.1 | 1.3 | -0.18 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 7 | 6.6 | 0.06 |
| Polycystic ovary syndrome | 7.1 | 2.7 | 1.63 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.5 | -0.67 |
| Primary sclerosing cholangitis | 1.3 | 3 | -1.31 |
| Psoriasis | 2.8 | 3.4 | -0.21 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.6 | 3.9 | 0.95 |
| Rosacea | 1.2 | 0.8 | 0.5 |
| Schizophrenia | 4.9 | 2.6 | 0.88 |
| scoliosis | 0.3 | 1.2 | -3 |
| Sjögren syndrome | 1.5 | 3.1 | -1.07 |
| Sleep Apnea | 2.2 | 1.6 | 0.38 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.3 | 1 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.2 | 0.6 | 1 |
| Stress / posttraumatic stress disorder | 2.4 | 2.1 | 0.14 |
| Systemic Lupus Erythematosus | 3.2 | 2.2 | 0.45 |
| Tic Disorder | 1.2 | 1.8 | -0.5 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.8 | 4.1 | -0.46 |
| Type 2 Diabetes | 7.6 | 7.4 | 0.03 |
| Ulcerative colitis | 3.6 | 6.7 | -0.86 |
| Unhealthy Ageing | 5.7 | 2.2 | 1.59 |
| Vitiligo | 2.5 | 1.3 | 0.92 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
